替雷利珠单抗辅助铂类方案化疗治疗晚期非小细胞肺癌的有效性及安全性分析

Efficacy and Safety Analysis of Tirizizumab Assisted Platinum Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨替雷利珠单抗辅助铂类方案化疗治疗晚期非小细胞肺癌(NSCLC)的有效性及安全性。方法选择2021年2月—2023年7月莒县人民医院收治的83例晚期NSCLC患者为研究对象,按随机数字表法将其分为观察组(n=42)及对照组(n=41)。对照组采用铂类方案化疗治疗,观察组在对照组基础上联合替雷利珠单抗治疗,两组均持续治疗3个周期。比较两组患者的临床疗效、肿瘤标志物水平及不良反应发生情况。结果观察组的治疗总有效率为71.43%,高于对照组的48.78%,差异有统计学意义(P<0.05)。治疗后,观察组的癌胚抗原、糖类抗原125、细胞角蛋白19的可溶性片段、鳞状上皮细胞癌抗原水平分别为(10.69±1.52)mg/mL、(41.54±3.49)U/mL、(4.89±1.05)mg/mL、(20.14±1.55)mg/mL,均低于对照组的(17.14±1.87)mg/mL、(53.69±4.21)U/mL、(7.17±1.32)mg/mL、(29.87±2.96)mg/mL,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用雷利珠单抗辅助铂类方案化疗治疗晚期NSCLC,可有效改善患者机体肿瘤标志物水平,且不会增加用药不良反应发生,安全性较高,临床效果显著。

Objective To investigate the efficacy and safety of tirelizumab assisted platinum chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Eighty-Three patients with advanced NSCLC admitted to Ju County People's Hospital from February 2021 to July 2023 were selected as the study objects,and were divided into an observation group(n=42)and a control group(n=41)according to random number table method.The control group was treated with platinum chemotherapy,and the observation group was treated with tirellizumab on this basis of the control group.Both groups were treated continuously for 3 cycles.The clinical efficacy,the levels of tumor markers and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 71.43%,which was higher than 48.78%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment and squamous cell carcinoma antigen in the observation group were(10.69±1.52)mg/mL,(41.54±3.49)U/mL,(4.89±1.05)mg/mL and(20.14±1.55)mg/mL,respectively,which were lower than(17.14±1.87)mg/mL,(53.69±4.21)U/mL,(7.17±1.32)mg/mL,(29.87±2.96)mg/mL in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of tirelizumab assisted platinum chemotherapy in the treatment of advanced NSCLC can effectively improve the levels of tumor markers in patients and will not increase the occurrence of adverse drug reactions,with high safety and significant clinical effects.